Karyopharm Therapeutics | KPTI - أصول متداولة





أصول متداولة تغيير تاريخ
AbbVie USD 37.48B 3.81B 2026-09
Abbott USD 23.5B 1.02B 2026-09
Amgen USD 34.36B 598M 2026-09
AstraZeneca USD 31.45B 3.48B 2026-09
BioCryst Pharmaceuticals USD 531.15M 46.47M 2026-09
Bristol-Myers Squibb USD 29.77B 1.19B 2026-09
Eli Lilly USD 65.26B 591M 2026-09
Enanta Pharmaceuticals USD 198.68M 5.65M 2025-12
GlaxoSmithKline GBP 17.9B 336M 2026-09
Incyte USD 5.52B 505.2M 2026-09
J&J USD 56.35B 3.42B 2026-09
Karyopharm Therapeutics USD 126.33M 23.19M 2026-03
MacroGenics USD 321.69M 139.16M 2026-06
Merck USD 38.94B 2.26B 2026-09
Nektar Therapeutics USD 589.04M 322.77M 2026-03
Novartis USD 28.75B 1.4B 2026-09
Novartis USD 28.75B 2.14B 2026-09
Pfizer USD 45.01B 3.65B 2026-09
Regeneron Pharmaceuticals USD 20.8B 2.35B 2026-09
Roche Holding CHF 35.44B 3.29B 2026-06
Sangamo BioSciences USD 49.89M 12.3M 2025-06
Takeda JPY 3T 153.11B 2026-09
Tectonic Therapeutic USD 231.1M 8.79M 2026-06
TG Therapeutics USD 1.17B 25.76M 2026-09
Ultragenyx Pharmaceutical USD 544M 62M 2026-09
Xencor USD 498.66M 24.55M 2026-09